{
  "docId": "019de073-42e0-708e-bbdb-4616fa343de3",
  "docSlug": "252a92bcbab8bda657ee7494bf765251",
  "documentTitle": "BioAtla | Investor Presentation Deck | 37 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 33,
  "pageCount": 37,
  "prevPage": 32,
  "nextPage": 34,
  "slideType": "traction",
  "function": "show_traction",
  "density": "balanced",
  "nDataPoints": 4,
  "notes": "The chart shows tumor volume over time for three different antibody treatments, with the CAB-EpCAM x CAB-CD3 showing the best efficacy.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-42e0-708e-bbdb-4616fa343de3/33",
  "deckHref": "/decks/019de073-42e0-708e-bbdb-4616fa343de3",
  "deckJsonHref": "/decks/019de073-42e0-708e-bbdb-4616fa343de3.json",
  "deckAnchorHref": "/decks/019de073-42e0-708e-bbdb-4616fa343de3#slide-33",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.55,
        "x": 0.03,
        "y": 0.275
      },
      "kind": "chart",
      "text": "Tumor volume over study days for three antibody treatments",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4a93bed3-4138-4b69-a11c-ae224abb368b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.38,
        "x": 0.59,
        "y": 0.28
      },
      "kind": "list",
      "text": "CAB-EpCAM x CAB-CD3 bispecific demonstrates efficient tumor shrinkage in a colorectal cancer cell line. In non-GLP and GLP tox studies in NHP, dual selection results in high selectivity: >160x higher therapeutic index, MTD not reached, No Cytokine release observed, Long half-life in Cyno (~4 days). These promising results will enable IND submission and Phase 1 initiation for multiple solid tumors 2H2022.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3fdbde44-2c39-401d-9129-6b7481af94ea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "Promising preclinical results with CAB-EpCAM x CAB-CD3 bispecific antibody",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9f3671eb-b1da-4f7c-8b24-ab4e36a0b693",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}